ciglitazone has been researched along with Cancer of Ovary in 6 studies
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ciglitazone alone, cisplatin alone, or their combination significantly suppressed the growth of OVCAR-3 tumors xenotransplated subcutaneously and prolonged the survival of mice with malignant ascites derived from DISS cells as compared with the control." | 3.77 | Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, and cisplatin enhances the inhibition of growth of human ovarian cancers. ( Mizunuma, H; Shigeto, T; Xin, B; Yokoyama, Y, 2011) |
| "Both meloxicam and ciglitazone treatments significantly suppressed the growth of OVCAR-3 tumors xenotransplanted subcutaneously and significantly prolonged the survival of mice with malignant ascites derived from DISS cells as compared with controls." | 3.74 | Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers. ( Futagami, M; Mizunuma, H; Shigeto, T; Xin, B; Yokoyama, Y, 2007) |
| "Ciglitazone is a peroxisome proliferator-activated receptor γ (PPARγ) agonist and improves insulin sensitivity." | 1.40 | Ciglitazone enhances ovarian cancer cell death via inhibition of glucose transporter-1. ( Cho, CH; Ha, E; Kim, JY; Kwon, SY; Mun, KC; Shin, SJ, 2014) |
| "CGZ and TGZ cause a decrease in ovarian cancer cell proliferation that is PPARγ independent." | 1.37 | Specific thiazolidinediones inhibit ovarian cancer cell line proliferation and cause cell cycle arrest in a PPARγ independent manner. ( Al-Alem, L; Curry, TE; Kilgore, MW; Southard, RC, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shin, SJ | 1 |
| Kim, JY | 1 |
| Kwon, SY | 1 |
| Mun, KC | 1 |
| Cho, CH | 1 |
| Ha, E | 1 |
| Bräutigam, K | 1 |
| Biernath-Wüpping, J | 1 |
| Bauerschlag, DO | 1 |
| von Kaisenberg, CS | 1 |
| Jonat, W | 1 |
| Maass, N | 1 |
| Arnold, N | 1 |
| Meinhold-Heerlein, I | 1 |
| Al-Alem, L | 1 |
| Southard, RC | 1 |
| Kilgore, MW | 1 |
| Curry, TE | 1 |
| Yokoyama, Y | 2 |
| Xin, B | 2 |
| Shigeto, T | 2 |
| Mizunuma, H | 2 |
| Vignati, S | 1 |
| Albertini, V | 1 |
| Rinaldi, A | 1 |
| Kwee, I | 1 |
| Riva, C | 1 |
| Oldrini, R | 1 |
| Capella, C | 1 |
| Bertoni, F | 1 |
| Carbone, GM | 1 |
| Catapano, CV | 1 |
| Futagami, M | 1 |
6 other studies available for ciglitazone and Cancer of Ovary
| Article | Year |
|---|---|
Ciglitazone enhances ovarian cancer cell death via inhibition of glucose transporter-1.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; beta Catenin; Cell Death; Cell Line, Tumor; Femal | 2014 |
Combined treatment with TRAIL and PPARγ ligands overcomes chemoresistance of ovarian cancer cell lines.
Topics: Apoptosis; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 8; Cell Line, Tumor; Chromans; | 2011 |
Specific thiazolidinediones inhibit ovarian cancer cell line proliferation and cause cell cycle arrest in a PPARγ independent manner.
Topics: Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chromans; Female; Gene Expression; Humans; Ovarian | 2011 |
Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, and cisplatin enhances the inhibition of growth of human ovarian cancers.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Ascites | 2011 |
Cellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cells.
Topics: Cell Cycle; Cell Survival; Down-Regulation; Female; Gene Expression Profiling; Humans; Ligands; Ovar | 2006 |
Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers.
Topics: Animals; Apoptosis; Ascites; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase | 2007 |